Novartis is paying Voyager Therapeutics $100 million up front to collaborate on gene therapies for Huntington’s disease and spinal muscular atrophy. The deal builds on a relationship the companies started in 2022.
Beth Hoffman, Origami Therapeutics CEO, talks about how the company's platform enables the discovery and development of protein degraders and conformation correctors to match the best drug to treat neurodegenerative diseases, such as Huntington's disease.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Ipsen is shoring up its neuroscience pipeline via a deal that gives it the option to license drugs that Exicure is developing for Huntington’s disease and Angelman syndrome. The programs are based on Exicure’s proprietary technology that produces nucleic acid therapies capable of delivery deep into the brain.
The companies will use a combination of more than seven years of medical record data with five years of prospective data on 5,000 MS patients, including real-world outcomes data and MRI images. Other disease areas to be explored include hematology and rare diseases.
Voyager will gain worldwide rights to its Huntington's disease therapy candidate, transfer rights to another product candidate to Neurocrine and pay Sanofi $20 million.
Neurodegenerative diseases represent a particularly interesting area for wearables to come into play as research scientists seek to better understand disease progression.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
“If it’s positive it’s a death sentence,” Filmmaker Marianna Palka says. “If it’s the opposite, I live like everyone else.” Palka has a 50/50 chance of developing Huntington’s disease. She watched her father become completely debilitated, to say the least, and two of her siblings have the disease. This genetic disease has been described as […]
CeNeRx BioPharma's investigational new drug application on a compound aimed at treating peripheral neuropathy has been approved by the U.S. Food and Drug Administration. The Cary, North Carolina-based company is now preparing to move forward in human trials of the compound.
Last week, CHDI Foundation, a not-for-profit research organization, said it would "initially" pay up to 50 percent of clinical costs of a drug/device therapy being developed by Medtronic and Alnylam Pharmaceutical to treat Huntington's disease. While medical device and biopharmaceutical companies are partnering more and more, the inclusion of the foundation in this trio is what's interesting.
Medtronic Inc. (NYSE:MDT) said Wednesday it will form an alliance with a pharmaceutical firm and research foundation to develop a unique drug/device therapy to treat Huntington's disease. The medical firm, based in Fridley, Minnesota, said it will partner with Alnylam Pharmaceutical Inc. (Nasdaq:ALNY) and the CHDI Foundation to deliver a cutting-edge drug technology directly to the brain using an implantable infusion system being developed by Medtronic.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The Cleveland Clinic Lou Ruvo Center for Brain Health will accept its first patients today. The Clinic will staff and manage the $100 million center that seeks to prevent the chronic symptoms of disabling brain diseases and to prolong healthy aging among people who are at risk for cognitive disorders or dementia.
Cleveland Clinic will expand into Las Vegas courtesy of a $100 million donation of the Frank Gehry designed Lou Ruvo Brain Institute. Ruvo is presenting the building as a gift to the Clinic, which will then operate the facility in Las Vegas. The center fights diseases including Alzheimer's and Parkinson's through both research and treatment.